SCLC Subtype-Enriched Biomarkers Define Positioning of Aurora B Inhibitor Combination with Venetoclax

C. Della Corte, C. Gay, J. Urosevic, U. Polanska, L. Ajpacaja, P. Wijnhoven, J. Wang,E. Coker,G. Fabbri, P. Jaaks, M. Jerome,J. Cosaert,M. Garnett,R. Cardnell,J. E. Pease, J. Travers,L. A. Byers

European journal of cancer（2020）

引用 0|浏览37

暂无评分

摘要

Background: Definition of subtypes in SCLC has provided a robust platform to guide molecularly specified monotherapy regimens in this disease. However, the aggressive nature of SCLC frequently limits the durability of monotherapies and requires development of combinations. We sought to use emerging subtype-specific resistance (BCL-2) and sensitivity (MYC) markers for the Aurora Kinase B inhibitor AZD2811 to guide rational positioning of novel combinations with an AZD2811 backbone.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要